Registration number:
JSL Complex Care Ltd
for the Period from 8 November 2023 to 31 December 2024
JSL Complex Care Ltd
(Registration number: 15270560)
Balance Sheet as at 31 December 2024
|
Note |
2024 |
||
|
Fixed assets |
|||
|
Investments |
|
||
|
Current assets |
|||
|
Debtors |
|
||
|
Cash at bank and in hand |
|
||
|
|
|||
|
Creditors: Amounts falling due within one year |
( |
||
|
Net current liabilities |
( |
||
|
Total assets less current liabilities |
|
||
|
Creditors: Amounts falling due after more than one year |
( |
||
|
Net assets |
|
||
|
Capital and reserves |
|||
|
Called up share capital |
|
||
|
Retained earnings |
|
||
|
Shareholders' funds |
|
||
For the financial period ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
|
• |
|
|
• |
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Approved and authorised by the
|
......................................... |
JSL Complex Care Ltd
Notes to the Unaudited Financial Statements for the Period from 8 November 2023 to 31 December 2024
|
General information |
The company is a private company limited by share capital, incorporated in England & Wales.
The address of its registered office is:
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' including the disclosure and presentation requirements of Section 1A and the Companies Act 2006.
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
The company's functional and presentation currency is pound sterling.
Summary of disclosure exemptions
The company has taken advantage of the exemption under Section 1AC.35 from disclosing transactions and balances with fellow group undertakings that are wholly owned.
Group accounts not prepared
Tax
The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.
JSL Complex Care Ltd
Notes to the Unaudited Financial Statements for the Period from 8 November 2023 to 31 December 2024
Investments
Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Dividends
Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.
Financial instruments
Basic financial assets, including trade and other receivables, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar asset. Such assets are subsequently carried at amortised cost using the effective interest method.
At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss and any subsequent reversal is recognised in profit or loss.
Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.
Financial liabilities
Basic financial liabilities, including trade and other payables, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.
|
Staff numbers |
The average number of persons employed by the company (including directors) during the period, was
JSL Complex Care Ltd
Notes to the Unaudited Financial Statements for the Period from 8 November 2023 to 31 December 2024
|
Investments |
|
2024 |
|
|
Investments in subsidiaries |
|
|
Subsidiaries |
£ |
|
Cost or valuation |
|
|
Additions |
|
|
Carrying amount |
|
|
At 31 December 2024 |
|
|
Debtors |
|
Current |
2024 |
|
Other debtors |
|
|
|
|
Creditors |
|
2024 |
|
|
Due within one year |
|
|
Loans and borrowings |
|
|
Amounts owed to group undertakings |
|
|
Accruals and deferred income |
|
|
|
Creditors include bank loans of £20,468 which are secured by a fixed charge and floating charge over the assets of the company.
|
2024 |
|
|
Due after one year |
|
|
Loans and borrowings |
|
Creditors include bank loans of £465,995 which are secured by a fixed charge and floating charge over the assets of the company.
Creditors include bank loans repayable by instalments of £368,516 due after more than five years.
JSL Complex Care Ltd
Notes to the Unaudited Financial Statements for the Period from 8 November 2023 to 31 December 2024
|
Share capital |
Allotted, called up and fully paid shares
|
2024 |
||
|
No. |
£ |
|
|
|
|
10 |
|
|
|
10 |
|
|
|
10 |
|
|
|
|
On the date of incorporation, the company issued 30 ordinary shares at £1.00 each.
|
Related party transactions |
|
Transactions with directors |
|
2024 |
At 8 November 2023 |
Advances to director |
At 31 December 2024 |
|
Interest free loan |
- |
|
|